Physician profile
Donald R Klasing
NPI 1508860230
$2,457.83
in general payments reported to CMS, 2019-2025
14 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.25 · 2022: $217 · 2023: $482 · 2024: $607 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,141.93 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $588.97 | 2022-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $550.63 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $228.09 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Abbvie INC. | $222.12 | 2023-2025 | |
| Corium, LLC | $211.72 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $143.14 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $110.89 | 2025 | Fanapt |
| Alkermes, INC. | $88.05 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $86.31 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.34 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $66.78 | 2023-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $49.39 | 2024-2025 | Abilify Maintena |
| Indivior INC. | $19.83 | 2025 | Sublocade |
| Axsome Therapeutics, INC. | $13.57 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Klasing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.